191 related articles for article (PubMed ID: 38456406)
1. Use of Sodium-Glucose Cotransporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real-World Data.
Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
J Am Heart Assoc; 2024 Mar; 13(6):e032783. PubMed ID: 38456406
[TBL] [Abstract][Full Text] [Related]
2. Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021-2022: an analysis of real-world data.
Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
medRxiv; 2023 Sep; ():. PubMed ID: 37732232
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
4. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
[TBL] [Abstract][Full Text] [Related]
5. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
[TBL] [Abstract][Full Text] [Related]
6. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.
Gonzalez J; Dave CV
BMC Cardiovasc Disord; 2024 May; 24(1):285. PubMed ID: 38816795
[TBL] [Abstract][Full Text] [Related]
7. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Chronic Heart Failure in Advanced Chronic Kidney Disease: The HAKA Multicenter Retrospective Real-World Study.
Quiroga B; Ortiz A; Núñez S; Kislikova M; González Sanchidrián S; Broseta JJ; Albines ZS; Escamilla Cabrera B; Rivero Viera Y; Rodriguez Santarelli D; Salanova Villanueva L; Lopez Rodriguez F; Cancho Castellano B; Ibáñez Cerezon M; Gutierrez Rivas CP; Aresté N; Campos Gutiérrez B; Ródenas Gálvez A; Glucksmann Pizá MC; Balda Manzanos S; Soldevila A; Rodríguez Gayo L; Moral Berrio E; Ortega Diaz M; Beltrán Catalán S; Puente García A; Ángel Rojas M; Sosa Barrios RH; Santana Zapatero H; Rangel Hidalgo G; Martinez Canet AM; Díez J;
Cardiorenal Med; 2024; 14(1):202-214. PubMed ID: 38513622
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
[TBL] [Abstract][Full Text] [Related]
10. The ability of modern therapy to improve the prognosis of patients with HF: role of angiotensin neprilysin inhibitors and sodium-glucose cotransporter inhibitors.
Mareev YV; Mareev VY
Kardiologiia; 2021 Jul; 61(6):4-10. PubMed ID: 34311683
[TBL] [Abstract][Full Text] [Related]
11. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study.
Jensen J; Poulsen MK; Petersen PW; Gerdes B; Rossing K; Schou M
ESC Heart Fail; 2023 Jun; 10(3):1745-1756. PubMed ID: 36852608
[TBL] [Abstract][Full Text] [Related]
13. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
Yan Y; Liu B; Du J; Wang J; Jing X; Liu Y; Deng S; Du J; She Q
ESC Heart Fail; 2021 Jun; 8(3):2210-2219. PubMed ID: 33749159
[TBL] [Abstract][Full Text] [Related]
14. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Treatments in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Systematic Review and Network Meta-Analysis.
Zafeiropoulos S; Farmakis IT; Milioglou I; Doundoulakis I; Gorodeski EZ; Konstantinides SV; Cooper L; Zanos S; Stavrakis S; Giamouzis G; Butler J; Giannakoulas G
JACC Heart Fail; 2024 Apr; 12(4):616-627. PubMed ID: 37656079
[TBL] [Abstract][Full Text] [Related]
16. Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review.
Ouyang X; Wang J; Chen Q; Peng L; Li S; Tang X
Cardiovasc Diabetol; 2023 May; 22(1):124. PubMed ID: 37226247
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of angiotensin receptor-neprilysin inhibitor and sodium-glucose cotransporter-2 inhibitors for patients with heart failure with reduced ejection fraction: a meta-analysis.
Huang Y; Fang C; Zhang Y; Ma L; Zhou H; Ye H
J Cardiovasc Med (Hagerstown); 2023 Feb; 24(2):123-131. PubMed ID: 36583980
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic Therapy for Heart Failure with Preserved Ejection Fraction.
Peters AE; DeVore AD
Cardiol Clin; 2022 Nov; 40(4):473-489. PubMed ID: 36210132
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Sreenivasan J; Malik A; Khan MS; Lloji A; Hooda U; Aronow WS; Lanier GM; Pan S; Greene SJ; Murad MH; Michos ED; Cooper HA; Gass A; Gupta R; Desai NR; Mentz RJ; Frishman WH; Panza JA
Cardiol Rev; 2024 Mar-Apr 01; 32(2):114-123. PubMed ID: 36576372
[TBL] [Abstract][Full Text] [Related]
20. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
Sobue Y; Watanabe E; Lip GYH; Koshikawa M; Ichikawa T; Kawai M; Harada M; Inamasu J; Ozaki Y
Heart Vessels; 2018 Apr; 33(4):403-412. PubMed ID: 29067492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
